Advancing the pre-clinical evaluation of a novel modular self-assembling and self-adjuvantin g multiepitope peptide-based nanoparticle tuberculosis vaccine candidate

Co Investigator

Tuberculosis is a leading infectious cause of death globally and is over-represented in indigenous people in FNQ. BCG is the only licensed TB vaccine universally for TB prevention in children, but fails in adults, and its protection wanes in adolescence. We have developed a novel modular self-assembling and self-adjuvanting multiepitope peptidebased nanoparticle tuberculosis vaccine named PNx6, which could significantly improve the immunity and protection efficacy of BCG in a murine model when used as a booster. This goal of this project is to analyse the immunogenicity and reactogenicity of PNx6 on human cells to advance its clinical translation potential.

09 Dec 2024 - 09 Dec 2026

N/A